ENvue Medical, Inc. (FEED)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5M 3M 4.5M Q3 '20: 620K Q4 '20: 623K Q1 '21: 612K Q2 '21: 661K Q3 '21: 1M Q4 '21: 1.7M Q1 '22: 1.9M Q2 '22: 2M Q3 '22: 1.6M Q4 '23: 2.3M Q1 '24: 2.9M Q2 '24: 3.4M Q3 '24: 3.3M Q4 '24: 2.6M Q1 '25: 2.7M Q2 '25: 2.3M Q3 '25: 2.7M Q4 '25: 2.6M Q1 '26: 2.2M Q2 '26: 1.9M Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-800K 0 800K 1.6M 2.4M Q3 '19: 326K Q4 '20: 214K Q1 '21: 240K Q2 '21: 410K Q3 '21: 539K Q4 '21: 770K Q1 '22: 799K Q2 '22: 872K Q3 '22: 724K Q4 '23: 1.5M Q1 '24: 2M Q2 '24: 2.2M Q3 '24: 2M Q4 '24: 1.5M Q1 '25: 1.2M Q2 '25: 750K Q3 '25: 806K Q4 '25: 153K Q1 '26: -271K Q2 '26: -502K Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '21: -4.7M Q4 '21: -5.7M Q1 '22: -5.5M Q2 '22: -5.8M Q3 '22: -5.8M Q4 '22: -5M Q1 '23: -5M Q2 '23: -4.7M Q3 '23: -4.4M Q4 '23: -3.4M Q1 '24: -2.9M Q2 '24: -2.6M Q3 '24: -2.9M Q4 '24: -3.6M Q1 '25: -4.9M Q2 '25: -8.2M Q3 '25: -9.4M Q4 '25: -22.9M Q1 '26: -24.7M Q2 '26: -26.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-24M -16M -8M 0 8M 16M 24M Q3 '21: -12.8M Q4 '21: -14.3M Q1 '22: -10.5M Q2 '22: -11.6M Q3 '22: -5.9M Q4 '22: -5.4M Q1 '23: -5.4M Q2 '23: -5.2M Q3 '23: -5M Q4 '23: -3.7M Q1 '24: -3.2M Q2 '24: -2.8M Q3 '24: -3.1M Q4 '24: -3.7M Q1 '25: -5M Q2 '25: -8.3M Q3 '25: -6.8M Q4 '25: -18.2M Q1 '26: -20.1M Q2 '26: -21.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 900K 1.8M 2.7M Q3 '21: 471K Q4 '21: 925K Q1 '22: 1.1M Q2 '22: 1.2M Q3 '22: 905K Q4 '22: 585K Q1 '23: 538K Q2 '23: 412K Q3 '23: 504K Q4 '23: 746K Q1 '24: 884K Q2 '24: 1.2M Q3 '24: 1.3M Q4 '24: 1.1M Q1 '25: 1.4M Q2 '25: 1.6M Q3 '25: 1.9M Q4 '25: 2.4M Q1 '26: 2.5M Q2 '26: 2.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '21: -4.8M Q4 '21: -4.4M Q1 '22: -5.2M Q2 '22: -5.2M Q3 '22: -6.6M Q4 '22: -7M Q1 '23: -6.5M Q2 '23: -5.7M Q3 '23: -4.4M Q4 '23: -3.6M Q1 '24: -3M Q2 '24: -2.3M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -3.3M Q2 '25: -6.1M Q3 '25: -7.2M Q4 '25: -9.4M Q1 '26: -12.3M Q2 '26: -11.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q1 '16: -1.6M Q2 '16: -1.5M Q3 '16: -1.5M Q4 '16: -1.5M Q1 '17: -1.6M Q2 '17: -1.6M Q3 '17: -1.8M Q4 '18: -3.6M Q4 '21: -4.4M Q4 '23: -3.6M Q1 '24: -3M Q2 '24: -2.3M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -3.3M Q2 '25: -6.1M Q3 '25: -7.3M Q4 '25: -9.4M Q1 '26: -12.4M Q2 '26: -11.7M Q2 '16 Q1 '17 Q4 '18 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q1 '21: 24.2M Q2 '21: 24.8M Q3 '21: 26.1M Q1 '22: 1.4M Q2 '22: 1.4M Q3 '22: 1.4M Q1 '23: 1.7M Q2 '23: 1.7M Q3 '23: 1.7M Q1 '24: 247K Q2 '24: 25.3K Q3 '24: 280.3K Q1 '25: 62.6K Q2 '25: 484.6K Q3 '25: 858.4K Q1 '26: 3.3M Q2 '26: 6.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-210.00 -140.00 -70.00 0.00 70.00 140.00 210.00 Q2 '20: -0.62 Q3 '20: -0.60 Q4 '20: -0.42 Q1 '21: -0.49 Q2 '21: -0.30 Q3 '21: -0.46 Q4 '21: -0.57 Q1 '22: -1.18 Q2 '22: -2.10 Q3 '22: -2.52 Q4 '22: -3.84 Q1 '23: -3.70 Q2 '23: -3.42 Q3 '23: -3.16 Q4 '23: -23.33 Q1 '24: -20.28 Q2 '24: -46.81 Q3 '24: -49.95 Q4 '24: -157.28 Q1 '25: -189.56 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.